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Abstract
Background: Culturing has long been the gold standard for detecting aetiologic agents in bacterial infections. In
some cases, however, culturing fails to detect the infection. To further investigate culture-negative samples,
amplification and subsequent sequencing of the 16S rRNA gene is often applied. The aim of the present study was
to compare the current method used at our Department of Clinical Microbiology, based on the MicroSeq ID system
(Applied Biosystems, USA) with the Universal Microbe Detection (UMD) SelectNA kit (Molzym, Germany).
Methods: 76 culture-negative samples were first processed with the MicroSeq ID analysis, where total DNA was
extracted and the 16S gene amplified and sequenced with the MicroSeq ID system. Samples were subsequently
processed with the UMD SelectNA analysis, where human DNA was removed during the DNA extraction procedure
and the 16S gene amplified in a real-time PCR and sequenced.
Results: 22 of 76 samples (28.9%) were positive for bacteria with the UMD SelectNA, which was significantly more
(p = 0.0055) than the MicroSeq ID where 11 of 76 samples (14.5%) were positive. The UMD SelectNA assay
identified more relevant bacterial pathogens than the MicroSeq ID analysis (p = 0.0233), but also found a number
of species that were considered contaminations.
Conclusions: The UMD SelectNA assay was valuable for the identification of pathogens in culture-negative
samples; however, due to the sensitive nature of the assay, extreme care is suggested in order to avoid false
positives.
Keywords: Culture-negative samples, Molecular diagnostics, Universal Microbe Detection, 16S PCR
Background
The standard method used in clinical microbiology la-
boratories for detection of bacterial and fungal patho-
gens is culturing of clinical specimens obtained from the
patients. However, in some infectious episodes, the
causative microorganism cannot be detected by cultur-
ing, even though the clinical signs and symptoms are
suggestive of an infection. The occurrence of culture-
negative results, when microorganisms are in fact
present, can be due to prior antibiotic treatment [1],
slow growing or fastidious microorganisms [2], or the
presence of viable but nonculturable bacteria [3].
Culture-negative results are for instance seen with in-
fective endocarditis [4], bone and joint infections includ-
ing foreign body associated infections [5], otitis media
[6], and meningitis [7].
Molecular methods have the potential to detect and
identify pathogens that are nonculturable. One such
method is PCR that identifies pathogens from their nu-
cleic acids. Several types of PCRs can be used depending
on purpose, such as species-specific PCRs, multiplex
PCRs that targets a panel of species, or broad-range
PCRs that potentially targets all species. At the
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Department of Clinical Microbiology at Rigshospitalet,
part of a tertiary-referral hospital, samples are received
from diverse infections with different etiologies. A
broad-range PCR assay was implemented seven years
ago in the department in order to identify pathogens in
culture-negative samples from patients with a suspected
infection. The method in use consists of a total genomic
DNA extraction from the clinical samples followed by
broad-range 16S rDNA PCR and sequencing analyses
employing the MicroSeq ID kit. This led to an improved
detection rate of infectious episodes when compared
with culturing. However, a substantial number of sam-
ples still tested negative for microorganisms despite
continued clinical suspicion of infection, indicating a
suboptimal sensitivity.
The commercial broad-range UMD assay (also
known as SepsiTest when performed on whole blood)
has previously been shown to have an increased posi-
tivity rate compared to culturing for a variety of sam-
ples [8–11]. The assay includes a DNA extraction, in
which human DNA is removed, followed by a PCR
amplifying regions of the 16S and 18S genes. The
assay has been reported by the company to have a
lower detection limit of 20–460 colony forming units
(CFU) per mL blood depending on species [12]. A
semi-automated version of the assay, i.e. the UMD
SelectNA, requiring less hands-on time has been de-
veloped since the previous studies. The aim of this
study was to compare the MicroSeq ID analysis with
the UMD SelectNA assay for the detection and iden-
tification of pathogens in culture-negative samples for
routine diagnostic purposes.
Methods
Sample collection
Samples from patients with a suspected infection were
collected under sterile conditions at either Rigshospitalet
(a tertiary referral hospital, 1361 bed units, approxi-
mately 264,000 inpatients annually) or Hvidovre
Hospital (a secondary referral hospital, 730 bed units,
approximately 83,000 inpatients annually), and sent to
the Department of Clinical Microbiology (DCM) at
Rigshospitalet during the period of June 2015 to October
2015. Sample types included tissue adjacent to joints
(27), other tissues (12), bone samples (9), body fluids (6),
heart valves (5), joint fluids (5), foreign bodies (3), spinal
fluids (3), pus (3), sonication fluids (2), E-swap (1).
Culture-negative samples, from patients with a sus-
pected infection, were subjected to MicroSeq ID 16S if
requested by the clinical doctor responsible for the treat-
ment of the patient. The same samples were subse-
quently processed with the UMD SelectNA assay.
Specimens were stored at 5 °C upon arrival at the DCM,
and processed within four weeks.
Culturing
All growth media were obtained from Statens Serum
Institute, Denmark. All samples were cultured for up to
5 days with the exception of heart valves that were cul-
tured up to 14 days. For culture conditions see Table 1.
The MALDI-TOF Biotyper (Bruker, Germany) was used
to identify isolates.
UMD SelectNA assay
DNA isolation
DNA isolation was performed with the UMD SelectNA
CE-IVD kit (Molzym, Germany) according to the manu-
facturer’s recommendation. In short, tissue samples were
pre-treated with proteinase K for 10 min. Body fluids,
swabs and tissues were treated with a chaotropic buffer,
lysing the human cells, and subjected to DNase treat-
ment to degrade the human DNA. DNA from potentially
present microorganisms was subsequently extracted in
the SelectNA instrument and stored at −20 °C until real-
time PCR analysis.
Real-time PCR
The real-time PCR assay was carried out with reagents
from the UMD SelectNA kit. Two PCRs were performed
for each sample: 1) a reaction amplifying the V3-V4 re-
gion of the bacterial 16S rDNA gene (481 bp); and 2) a
control reaction amplifying a DNA fragment that was
added during the DNA extraction to evaluate the effi-
ciency of the extraction. The SYBR green based real-
time PCR was perfomed in a LightCycler 480 instrument
(Roche, Switzerland) with the following conditions:
95 °C for 1 min; 40 cycles of 95 °C for 5 s, 55 °C for
10s and 72 °C for 25 s followed by a melting curve
analysis (70–95 °C). Samples with a melting
temperature (Tm) value between 87 and 91 °C for the
16S were considered positive.
Sequencing
PCR products from positive samples were purified
with the QIAquick PCR purification kit (Qiagen,
Netherlands). Sequencing primers included in the
UMD SelectNA kit were used for Sanger sequencing,
performed by Macrogen (Amsterdam, Netherland).
Sequences were initially aligned to the SepsiTest BLAST
database (http://www.sepsitest-blast.de) and subsequently
if no bacterial species was identified by the database,
to the NCBI BLAST database (http://www.ncbi.nlm.
nih.gov/BLAST/). Sequences with ≥97–99% or ≥99%
identity to the database were assigned to genus level
or species level, respectively. Mixed bacterial se-
quences were analyzed with the RipSeq mixed pro-
gram (Pathogenomix, USA) to resolve the individual
sequences [13].
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Precautions to avoid contamination
DNA isolation and addition of DNA to the PCR was car-
ried out in a laminar flow bench in a room designated
for extraction procedures. The master mix was prepared
in a laminar flow bench in a DNA-free master-mix
room. All surfaces of benches and equipment were
cleaned with the disinfectant Virkon (Virkon Disinfectant
Technologies, UK) before use. A 1 h UV decontamination
program was performed on the SelectNA instrument be-
fore every use. Sterile elbow-long gloves and designated
lab coats were used at all times.
MicroSeq ID 16S analysis
DNA isolation
Samples were processed with the DNeasy Blood and
Tissue kit (Qiagen, Netherlands) according to the manu-
facturer’s tissue protocol with a few modifications: after
56 °C incubation with proteinase K for 2–3 h, samples
were incubated for additional 10 min at 95 °C, and the
final elution volume was 100 μL AE buffer. DNA solu-
tions from all tissue samples were diluted 1:40 in
nuclease-free water.
PCR
The MicroSeq 500 16S rDNA PCR (Applied Biosystems,
United States) was used to amplify the V1-V2 region
of the 16S. Sample DNA and the master mix were
mixed in a 1:1 ratio and the reaction was carried out
in a 9800 Fast Thermal Cycler (Applied Biosystems,
USA) with the following conditions: initial denatur-
ation of 95 °C for 10 min and 30 cycles of 95 °C for
30s, 60 °C for 30 min and 72 °C for 45 s, followed by
a final extension of 72 °C for 10 min. PCR products
were resolved by electrophoresis on a 2% agarose gel
(Embi Tech, United States). Samples with a 500–
600 bp PCR fragment were purified with the ExoSap-IT
kit (Affymetrix, United States).
Sequencing
PCR products were sequenced with the MicroSeq 500 16S
Seq kit (Applied Biosystems, United States) according to
manufacturer’s instructions. Products were then purified
with gel filtration cartridges (Edge Bio, Unites States)
and sequenced on a 3130xl Genetic Analyzer (Applied
Biosystems, Unites States). The MicroSeq ID software
was used to identify the species and in cases with low
match % the sequence was additionally aligned to the
NCBI BLAST database.
Precautions to prevent contamination
DNA extraction and PCR setup was performed in a pre-
amplification room separated from the post-amplification
room where the sequencing was performed. Gloves and
designated lab coats were applied.
Evaluation of results and statistics
A comparison was performed on the sequencing re-
sults obtained by the two methods and other findings
from the same patient, including: culturing, molecular
analyses, histopathology and serology. A finding was
considered a relevant pathogen when the same organ-
ism was identified in another sample from the same
patient by culturing or molecular analysis, or when
histopathology or serology supported the finding.
Findings with no such support were considered am-
biguous. McNemar’s test was performed on 2 × 2
contingency Tables. A p-value below 0.05 was consid-
ered significant.
Results
Positivity rate of the two methods
76 culture-negative samples originating from 46 patients
were processed with both the MicroSeq ID analysis and
the UMD SelectNA assay. A total of 22 samples (28.9%)
were positive with the UMD SelectNA assay, which was
significant more compared to the 11 positive samples
(14.5%) with the MicroSeq ID (p = 0.0055) (Table 2).
Table 1 Culturing conditions
Anaerobic plates
(anaerobic conditions)
Chocolate agar plates
(aerobic, 5% CO2)
Blood agar plates
(aerobic, 5% CO2)
Eosin methylene
blue plates (aerobic)
Brain heart infusion
agar plates (anaerobic)
Thioglycolate
broth (aerobic)
Serum bouillon
broth (aerobic)
Soft tissue and
body fluids
X X X X X X
Bone samples X X X X X
Heart valves X X X X
Pus samples X X X X X
Table 2 Summary of all results
All samples MicroSeq ID
UMD SelectNA + − Total
+ 10 12 22
− 1 53 54
Total 11 65 76
+ = positive, − = negative. A McNemar’s test was performed, p = 0.0055
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Concordance
Ten samples were positive with both the MicroSeq ID
analysis and the UMD SelectNA analysis (Table 3). The
same organisms were found with the two methods with
the exception of one pus sample from a cerebral abscess,
which showed only partial concordance. The MicroSeq
ID identified Fusobacterium nucleatum and Parvimonas
micra while the UMD SelectNA identified Dialister
pneumocitis and Parvimonas micra (ID 3). All identified
species are common pathogens found in abscesses with
an odontogenic origin and therefore considered clinically
relevant [14].
Discordance
Twelve samples were positive with the UMD SelectNA
analysis and negative with the MicroSeq ID analysis,
whereas only one sample was positive with the MicroSeq
ID analysis and negative with the UMD SelectNA ana-
lysis (Table 4). The results were compared to other find-
ings from the patients obtained within the last year in
order to evaluate the relevance of the findings, and
based on this categorized as either relevant findings (R)
or ambiguous findings (A).
The UMD SelectNA identified relevant pathogens in 7
samples (ID 6, 9–12) of which the MicroSeq ID analysis
were negative. One relevant pathogen, i.e. Toxoplasma
gondii, was only detected by the MicroSeq ID (ID 13,
cerebral abscess). The number of positive samples with
relevant bacterial species were significantly higher using
the UMD SelectNA compared to the MicroSeq ID
(p = 0.0233) (Table 5). In the remaining 5 samples bac-
terial species were considered ambiguous findings be-
cause the results were not confirmed by other findings.
The Bacillus species and Thiothrix flexilis detected in
tissue located adjacent to an infected prosthesis (ID 14)
were most likely contaminants as where the Staphylococ-
cus epidermidis found in a lymph node from a lymphoma
patient (ID 18). Kocuria rhizophila (ID 15, pericarditis)
and Bergeyella sp. H1890 (ID 17, spondylodiscitis) have
been reported to cause human disease [15, 16] while Cloa-
cibacterium normanense (ID 17, spondylodiscitis) and
Hymenobacter arizonensis (ID 16, spondylodiscitis) are
not typically associated with human infections, but have
been detected at surgical wound sites [17].
Discussion
Seventy-six culture-negative samples from patients with
suspected infection were analyzed with the MicroSeq ID
analysis and the UMD SelectNA analysis. The UMD
SelectNA method identified significantly more relevant
bacterial pathogens than the MicroSeq ID analysis, and
thus proved to be a more sensitive analysis for detecting
bacteria. It is possible that the removal of human DNA
during the UMD SelectNA method explains the higher
sensitivity, since excessive amounts of human DNA has
been shown to inhibit the 16S PCR reaction [18]. The
singule case (ID 13) where the MicroSeq ID analyses de-
tected a pathogen not detected by the UMD SelectNA
analysis was in a pus sample from a cerebral abscess. In
this case the intracellular parasite Toxoplasma gondii
was identified as demonstrated earlier with this method
[19]. It is possible that the chaotropic buffer intended to
lyse the human cells during the UMD SelectNA DNA
extraction disrupted the membrane of the parasite and
exposed the DNA to the DNase activity.
In another case of cerebral abscess (ID 3) the two
methods identified different oral-cavity-derived bacterial
species that were all considered relevant. Often multiple
Table 3 Concordant result of the UMD SelectNA and MicroSeq ID methods
Patient ID Sample type Indication UMD SelectNA result MicroSeq ID result Other findingsa
1 Aorta tissue Endocarditis Streptococcus pyogenes S. pyogenes S. pyogenes cultured from
blood sample
2 Heart valve tissue Endocarditis Staphylococcus aureus/simiae S. aureus S. aureus cultured from
blood sample
3 Pus Cerebral abscess Dialister pneumocitis &
Parvimonas micra
Fusobacterium nucleatum &
P. micra
F. nucleatum cultured from
blood sample
4 Seroma fluid Breast cancer Streptococcus mitis/oralis S. mitis
5 Pus Abscess in fossa iliaca Streptococcus intermedius S. intermedius
6 Tissue Infected hip prosthesis Streptococcus dysgalactiae
equisimilis
S. dysgalacticae equisimilis
Tissue S. dysgalactiae equisimilis S. dysgalacticae equisimilis
Tissue S. dysgalactiae equisimilis S. dysgalacticae equisimilis
7 Aorta valve Endocarditis S. pyogenes S. pyogenes
8 Aorta valve Endocarditis Streptococcus anginosus S. anginosus S. anginosus cultured from
blood samples
aFindings from other sample taken from the same patient
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species are associated with cerebral abscesses of odonto-
genic origin [14], and it is well known that Sanger se-
quencing of the 16S gene is limited to detecting two or
perhaps three species [20]. In order to obtain a higher
resolution, next generation sequencing must be applied.
In addition to the relevant pathogens, the UMD
SelectNA method also identified a number of ambiguous
findings. The broad-range nature of the assay combined
with the low detection limit make the assay sensitive to
contamination, since only a few bacteria introduced dur-
ing sampling, handling or processing of the sample will
give rise to a positive result. A limitation in this study
was that the UMD SelectNA assay was performed on
leftover material. Patient samples were primarily used
for culture-based identification, subsequently for the 16S
MicroSeq ID analyses and finally for the UMD SelectNA
assay. Therefore, it is possible that samples were con-
taminated in the process of handling. However, similar
studies evaluating the manual version of the UMD assay
found a corresponding number of unlikely bacteria in
different clinical specimens that they considered envir-
onmental contaminants [21, 22]. Haag et al. [21] states
that material already processed for other purposes than
molecular diagnosis is of limited value and that samples
should be spilt upon arrival to the laboratory . However,
at our Department of Clinical Microbiology, molecular
analysis is often ordered after culturing has proven
negative, and due to the large number of samples
received every day it is not feasible to divide all the
samples in case they are send for molecular analysis
later. Thus, in this study we have demonstrated that
samples used for culturing can still be of value for
detecting relevant pathogens with molecular methods.
Also, it cannot be excluded that the rare bacterial species
identified with the UMD SelectNA assay are causative of
the infection. Indeed, these events should be monitored
to elucidate their true nature.
Samples were stored at 5 °C to avoid potential cell dis-
ruption from freezing and thawing that would result in
digestion of exposed microbial DNA and the occurrence
of false negatives with the UMD SelectNA. To evaluate
the possible contamination risk of storing the samples at
Table 4 Discordant result of the UMD SelectNA and MicroSeq ID methods
Patient ID Sample type Indication UMD SelectNA result MicroSeq ID result Other findings Conclusion
6 Tissue Infected hip prosthesis S. dysgalactiae equisimilis − S. dysgalactiae equisimilis found
with 16S in 3 other samples
from the patient
R
9 Tissue Mycotic aneurism S. pneumoniae − Cocci found in blood culture
bottle and positive antibody
reaction for pneumococci
R
10 Tissue Spinal implant infection Staphylococcus lundunensis/
hominis
− Staphylococcus hominis cultured
from tissue sample
R
11 Tissue Infected knee prosthesis S. aureus/simiae − S. aureus cultured from tissue R
Tissue S. aureus/simiae − R
12 Tissue Infected hip prosthesis Staphylococcus epidermidis/
caprae/capitis
− S. epidermidis cultured in 3 out
of 5 biopsies
R
R
Tissue S. epidermidis/caprae/capitis −
13 Tissue Cerebral abscess − Toxoplasma gondii
(parasite)
R
14 Tissue Infected hip prosthesis Bacillus sp. & Thiotrix sp. − Two other tissue samples
negative with the UMD and
routine 16S/28S
A
15 Fluid from pacemaker
electrode
Pericarditis Kocuria rhizophila − Two other samples negative
with UMD and routine 16S/28S
A
16 Implantation material Spondylodiscitis Hymenobacter arizonensis − Other implant material sample
negative with UMD and routine
16S/28S
A
17 Tissue Spondylodiscitis Cloacibacterium normanense &
Bergeyella sp. H1890
− Fluid from back negative with
UMD and routine 16S/28S
A
18 Lymph node Lymphoma S. epidermidis − A
Table 5 Results of samples with relevant bacterial species only
Samples with relevant bacteria MicroSeq ID
UMD SelectNA + − Total
+ 10 7 17
− 0 59 59
Total 10 66 76
+ = positive for a relevant bacterial species, − = negative for a relevant
bacterial species. A McNemar’s test was performed, McNemar’s test p = 0.0233
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this temperature, seven bone samples from healthy do-
nors where processed with the UMD SelectNA both
upon arrival at the Department of Clinical Microbiology
and 4 weeks later. All 16S real-time PCR reactions were
negative, indicating that no contamination had occurred
(data not shown).
Even with the increased sensitivity of the SelectNA
analysis the majority of the samples were negative
(70.7%). This could be due to 1) the patient did not have
an infection, 2) the amount of bacteria in the sample
was below the detection limit of the method or 3) the
sample did not contain any bacteria even though the pa-
tient had an infection. Many of the samples in this study
were collected from patients with chronic infections
where it has been shown that the bacteria are not homo-
geneously distributed at the infectious site [23, 24], and
that they can be caused by bacteria growing in small bio-
films down to 5 μm [25]. In these cases, sampling of the
infected area is extremely difficult. At least two patients
with negative results did have an infection. Three bone
samples from one patient, suspected of having a tubercu-
losis osteomyelitis, were positive with a Mycobacterium-
tuberculosis-specific PCR performed at another diagnostic
laboratory (State Serum Institute, SSI). Additionally, an-
other patient suspected of having an atypical mycobacter-
ial infection tested positive for Mycobacterium avium at
the SSI. Mycobacteria species are included in the list of
bacteria that can be detected by the assay, but the thick
cell wall of mycobacteria species has previously proved to
be difficult to disrupt [26, 27]. It is possible that the chem-
ical and enzymatic lysis in the UMD SelectNA assay is not
sufficient for disrupting the mycobacterial cells.
This study is, to the authors’ knowledge, the first to re-
port on the performance of the semi-automated version
of UMD assay, i.e. the SelectNA, which has a definite
shorter hands-on time than the manual version. Com-
parison of this study to previously published studies of
the manual version is somewhat difficult due to the dif-
ference of study design and sample types. All previous
studies have compared the UMD assay (or SepsiTest)
with culturing, in contrast to this study where all sam-
ples included were culture negative, consequently they
were able to calculate sensitivity and specificity of the
method by comparing to culturing results. Whether it is
relevant to use culturing as the gold standard when
culturing does not find all pathogens is debatable. Here
it was chosen not to calculate sensitivity and specificity
for the methods in lack of a reliable gold standard. Kühn
et al. applied the method for diagnosis of infectious
endocarditis and reported a sensitivity of 85% with the
UMD [11]; this study likewise found a high positivity
rate for heart valves with three out of five positive for
relevant pathogens. Haag et al. found 37.9% culture-
negative but PCR positive with the UMD assay, which
is more than the 28.9% found in this study [21]. A
possible explanation of this discrepancy might be that
Rigshospitalet is a large tertiary referral hospital with
patients suffering from rare diseases where the etiology
is difficult to elucidate. In any case both studies dem-
onstrate that the UMD is applicable to many different
samples types, which is convenient in a diagnostic labora-
tory receiving many different sample types. Recently, a
new version of the SelectNA instrument fully automating
the DNA extraction for fluid samples and only requiring a
short manual pre-treatment for tissue has been developed.
The DNA extraction involves less hands-on time and is
currently being tested at the Department.
Conclusion
In summary, the UMD SelectNA assay was found to be
more sensitive than the MicroSeq ID analysis currently
used at the Department of Clinical Microbiology, and
therefore valuable for detecting pathogens in culture-
negative samples. Because of the increased sensitivity,
the assay is sensitive to contamination. Therefore, asep-
tic handling of the samples and a thorough clinical
evaluation of the patient’s history is vital in order to
assess the relevance of the findings.
Abbreviation
PCR: Polymerase chain reaction; UMD: Universal Microbe Detection
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